ABSTRACT

Objective: This study aimed to examine patient accessibility to new anticancer drugs including reimbursement coverage, time to listing, and listing price during the recent 3 years after the introduction of alternative pricing and reimbursement pathways in South Korea.

Methods: Anticancer drugs were selected for analysis from the new drugs reviewed from January 2017 to March 2020. Descriptive statistics were used to present the levels of the listing prices. Pearson’s correlation analysis was used to analyze the relationship between the list price in comparison to the External Reference Price(ERP) and the time to listing.

Results: Thirty-two anticancer drugs were included in analysis. The average time to listing for these drugs was 36.7 months. The ratio of the listing price in comparison with Average Adjusted Price from seven reference countries was from 12.6% to 90.2%. Pearson’s correlation coefficient for the correlation between the ratio of the listing price to the ERP and the time to listing was −0.37 and was statistically significant (p = 0.035).

Conclusions: Policies that relate to the scope of reimbursement, time to reimbursement, and list price should be able to equally reflect patient accessibility and national health insurance finances, as well as the impact on industry as a whole.

摘要

目的：本研究旨在调查韩国引入替代定价和报销途径后近 3 年内患者对新型抗癌药物的可及性，包括报销范围、上市时间和上市价格。

方法：从2017年1月至2020年3月审评的新药中选取抗癌药物进行分析，采用描述性统计方法呈现上市价格水平。使用 Pearson 相关分析来分析与外部参考价格 (ERP) 相比的标价与上市时间之间的关系。

结果：32种抗癌药物被纳入分析。这些药物上市的平均时间为 36.7 个月。上市价格与来自七个参考国家的平均调整价格的比率为 12.6% 至 90.2%。挂牌价格与 ERP 之比与挂牌时间之间的相关性的 Pearson 相关系数为 -0.37，具有统计学意义（p = 0.035）。

结论：与报销范围、报销时间和定价相关的政策应该能够平等地反映患者可及性和国家健康保险财务状况，以及对整个行业的影响。